EP0274445A2 - Additif de milieu de culture sans sérum et son utilisation - Google Patents

Additif de milieu de culture sans sérum et son utilisation Download PDF

Info

Publication number: EP0274445A2
Authority: EP; European Patent Office
Prior art keywords: serum; additive; growth medium; free growth; medium additive
Prior art date: 1987-01-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP19880300121

Other languages

German (de)

English (en)

Other versions

EP0274445B1 (fr

EP0274445A3 (en

Inventor

Kjell Bertheussen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Medi-Cult AS

Original Assignee

Medi-Cult AS

GEA Farmaceutisk Fabrik AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-01-09

Filing date

1988-01-08

Publication date

1988-07-13

1988-01-08 Application filed by Medi-Cult AS, GEA Farmaceutisk Fabrik AS filed Critical Medi-Cult AS

1988-01-08 Priority to AT88300121T priority Critical patent/ATE92098T1/de

1988-07-13 Publication of EP0274445A2 publication Critical patent/EP0274445A2/fr

1989-12-13 Publication of EP0274445A3 publication Critical patent/EP0274445A3/en

1993-07-28 Application granted granted Critical

1993-07-28 Publication of EP0274445B1 publication Critical patent/EP0274445B1/fr

2008-01-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000654 additive Substances 0.000 title claims abstract description 47
230000000996 additive effect Effects 0.000 title claims abstract description 47
239000001963 growth medium Substances 0.000 title claims abstract description 35
210000004027 cell Anatomy 0.000 claims abstract description 27
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 23
229910052742 iron Inorganic materials 0.000 claims abstract description 11
239000000203 mixture Substances 0.000 claims abstract description 11
239000013522 chelant Substances 0.000 claims abstract description 9
239000011573 trace mineral Substances 0.000 claims abstract description 9
235000013619 trace mineral Nutrition 0.000 claims abstract description 9
238000012360 testing method Methods 0.000 claims abstract description 8
GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 claims abstract description 6
210000004408 hybridoma Anatomy 0.000 claims abstract description 6
210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 4
210000004881 tumor cell Anatomy 0.000 claims abstract description 4
239000003513 alkali Substances 0.000 claims abstract description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract 12
239000003102 growth factor Substances 0.000 claims abstract 3
210000002966 serum Anatomy 0.000 claims description 18
239000002609 medium Substances 0.000 claims description 15
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
239000002184 metal Substances 0.000 claims description 8
229910052751 metal Inorganic materials 0.000 claims description 8
238000004113 cell culture Methods 0.000 claims description 7
230000012010 growth Effects 0.000 claims description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
230000010261 cell growth Effects 0.000 claims description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
150000002739 metals Chemical class 0.000 claims description 6
239000007640 basal medium Substances 0.000 claims description 5
239000012980 RPMI-1640 medium Substances 0.000 claims description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
239000007995 HEPES buffer Substances 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
-1 Na-pyruvate Chemical compound 0.000 claims description 2
229910052802 copper Inorganic materials 0.000 claims description 2
229910052725 zinc Inorganic materials 0.000 claims description 2
LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical group [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 claims 3
239000012141 concentrate Substances 0.000 claims 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
229930182816 L-glutamine Natural products 0.000 claims 1
229910052782 aluminium Inorganic materials 0.000 claims 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
229910052804 chromium Inorganic materials 0.000 claims 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims 1
150000002500 ions Chemical class 0.000 claims 1
229910052748 manganese Inorganic materials 0.000 claims 1
229920001993 poloxamer 188 Polymers 0.000 claims 1
238000012372 quality testing Methods 0.000 abstract description 2
239000000243 solution Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
102000004338 Transferrin Human genes 0.000 description 4
108090000901 Transferrin Proteins 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
239000012679 serum free medium Substances 0.000 description 4
239000012581 transferrin Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
231100000167 toxic agent Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
239000012535 impurity Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000004017 serum-free culture medium Substances 0.000 description 2
FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
206010022971 Iron Deficiencies Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000002585 base Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
102000006834 complement receptors Human genes 0.000 description 1
108010047295 complement receptors Proteins 0.000 description 1
238000012136 culture method Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000006175 metal-ion buffer Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008635 plant growth Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin

Definitions

the present invention concerns a serum-free medium additive which may be used when culturing cells which require iron in the growth medium.
the serum-free growth medium additive according to the invention may additionally be used to test the quality of growth media.
the serum-free additive By using the serum-free additive according to the present invention, the above disadvantages are avoided, and such a medium will in addition be very well suited for culturing and storing cells and tissued in vitro.
a complete medium with this additive will be precisely defined, be serum free and protein-free (except for a possible small quantity of insulin which is required by some cells, and which is used where necessary) and contain iron and trace elements in the form of stabilized chelated elements or compounds with transferrin or lipids being present. It is also very inexpensive to produce the additive according to the invention.
the medium according to the invention was produced, on the bases of a Fe/trace element buffer of synthetic non-protein chelants and such that the main problem, precipitation of metals at 37°C (see above), was solved by adding certain chelants which in combination in solution have very different and unique properties compared to each chelant alone.
the serum-free growth medium additive of the invention comprises
An additive according to the present invention may, e.g., be prepared by adding a concentrated solution of each of the components to pure water (it is of great importance to use water of highest possible purity such as for instance "Travenol" sterile water, when preparing the medium according to the invention).
a concentrated mixture is given below, where there is produced a composition which may be used in a 1000-fold concentration:
the pH of the composition is preferably adjusted to 4.5-5.0.
trace elements may, e.g., be carried out be the aid of a stock solution which may be prepared as follows. That solution will have a 100 000 fold concentration of that to be used in the medium.
Zn, Cu and chelants EDTA and citrate
the final pH should be between 4.0 and 4.5.
composition of trace elements may contain elements other than those given in the table above, depending on the requirements of the tissue of cell types to be used.
the additive according to the invention may, besides the components mentioned hereinbefore contain growth stimulating and necessary compounds for cell growth.
Such compounds may comprise for instance the surfactant "Pluronic" F 68 (20 mg/1), D-glucose (2.5 g/1), L-glutamine (2 mM), Na-pyruvate (1 nM), insulin (0.5 mg/1) or ethanolamine (20 ⁇ M). All the concentrations shown in brackets refer to final concentrations.
a composition for the addition of the compounds mentioned (except of ethanolamine which is a liquid at room temperature) may be produced as a dry product and as such this may be stored during long periods of time, up to several years.
Ethanolamine may, if necessary, be added to the medium to a desired concentration when using the composition. Ethanolamine is most frequently used in experiments with hybridoma cells when producing monoclonal antibodies.
a preferred basal medium to which the growth medium additive according to the present invention may be added is RPMI 1640 containing 2.5g/l NaHCO3 and 20mM HEPES (N-2-hydroxyethylpiperazine-N,N ⁇ -2-ethanesulphonic acid).
Preferred cell cultures for which the serum-free additive according to the invention have proven to be especially useful is the L 929 mouse fibroblast cell line, the HeLa hyman tumor cell line, various mouse and human B hybridoma cells which all produce monoclonal anti-bodies in quantities corresponding to growth in serum-containing cultures, and human monocytes which differentiate to developed macrophages during 7 days while keeping their complement receptors.
a particularly preferred use of the present additive is carried out with fast-growing types of cells for testing the quality of various types of media.
the growth medium additive according to the invention together with fast-growing cells as mentioned may be incorporated into a test-kit comprising, e.g., the additive (serum substitute) according to the invention, frozen cells (for instance on frozen carbondioxide) and optionally a medium (e.g. RPMI 1640) and culture equipment of plastics or other suitable material.
a test-kit comprising, e.g., the additive (serum substitute) according to the invention, frozen cells (for instance on frozen carbondioxide) and optionally a medium (e.g. RPMI 1640) and culture equipment of plastics or other suitable material.
Preferred fast-growing cells for use in testing fullg growth media are cells of a fast-growing cell line of which a cell culture has been deposited at the European Collection of Animal Cell Cultures, Porton Down, Salisbury, Wiltshire SP4 0JG on November 20, 1986, under the accession number 86112001.
This cell type is a special kind of fast-growing cell type of hybridoma cells prepared by the fusion of p3U1 tumor cells with B-lymphocytes.
This cell line has proven to be especially useful at quality testing of full growth media and as such is a particular aspect of the present invention.

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Plant Substances (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP19880300121 1987-01-09 1988-01-08 Additif de milieu de culture sans sérum et son utilisation Expired - Lifetime EP0274445B1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AT88300121T ATE92098T1 (de)	1987-01-09	1988-01-08	Serumfreie kulturmittelzutat und ihre verwendung.

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NO870095		1987-01-09
NO870095A NO162160C (no)	1987-01-09	1987-01-09	Serumfritt vekstmedium, samt anvendelse derav.

Publications (3)

Publication Number	Publication Date
EP0274445A2 true EP0274445A2 (fr)	1988-07-13
EP0274445A3 EP0274445A3 (en)	1989-12-13
EP0274445B1 EP0274445B1 (fr)	1993-07-28

Family

ID=19889567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19880300121 Expired - Lifetime EP0274445B1 (fr)	1987-01-09	1988-01-08	Additif de milieu de culture sans sérum et son utilisation

Country Status (16)

Country	Link
US (2)	US5045467A (fr)
EP (1)	EP0274445B1 (fr)
JP (2)	JPH0697996B2 (fr)
KR (1)	KR880009124A (fr)
AT (1)	ATE92098T1 (fr)
AU (1)	AU596491B2 (fr)
BR (1)	BR8800040A (fr)
CA (1)	CA1321961C (fr)
DE (1)	DE3882540T2 (fr)
DK (1)	DK169765B1 (fr)
ES (1)	ES2008411A6 (fr)
FI (1)	FI87230C (fr)
IL (1)	IL85026A (fr)
IT (1)	IT1215675B (fr)
NO (1)	NO162160C (fr)
NZ (1)	NZ223139A (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01153085A (ja) *	1987-10-29	1989-06-15	E I Du Pont De Nemours & Co	ハイブリドーマ増殖用培地
EP0432952A1 (fr) *	1989-12-07	1991-06-19	Snow Brand Milk Products Co., Ltd.	Milieu de culture sans sérum
WO1993000423A1 (fr) *	1991-06-21	1993-01-07	Novo Nordisk A/S	Additif pour milieu de culture a base de chelate de fer
WO1994002592A1 (fr) *	1992-07-24	1994-02-03	Celltech Limited	Culture de cellules animales
WO1994025599A1 (fr) *	1993-04-26	1994-11-10	Biotechnolog Forschung Gmbh	Lignees cellulaires de mammiferes et procede de preparation de glycoproteines
WO1998024883A3 (fr) *	1996-12-04	1998-10-01	Medi Cult As	Milieux de cultures cellulaires sans serum
EP0872487A3 (fr) *	1997-04-18	1999-10-27	Bayer Corporation	Préparation de facteur VIII recombinant en milieu sans protéine
WO2001016294A3 (fr) *	1999-08-27	2001-09-07	Invitrogen Corp	Composes de liaison metallique et leur utilisation dans des compositions de milieu de culture cellulaire
EP0929662A4 (fr) *	1996-03-18	2002-12-04	Univ Pittsburgh	Milieux de culture cellulaire pour cellules de mamiferes
US6767741B1 (en)	1999-08-27	2004-07-27	Invitrogen Corporation	Metal binding compounds and their use in cell culture medium compositions
EP1482031A1 (fr) *	1996-08-30	2004-12-01	Invitrogen Corporation	Milieu de culture de cellules de mammifères exempt de sérum
US20110212523A1 (en) *	2008-11-11	2011-09-01	Yukio Kato	Differentiation-inducing culture medium additive and use thereof
EP2390263A1 (fr)	2005-08-26	2011-11-30	Ares Trading S.A.	Procédé pour la préparation d'interféron bêta glycosylé
EP3122770A4 (fr) *	2014-03-23	2017-08-23	Advantech Bioscience Farmacêutica Ltda.	Amélioration de l'expression de protéines recombinantes avec du cuivre
CN110835622A (zh) *	2018-08-16	2020-02-25	上海药明生物技术有限公司	用于调节哺乳动物细胞乳酸代谢的培养基及其应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8801537D0 (sv) *	1988-04-26	1988-04-26	Ellco Food Ab	Cellodlingsmedium samt forfarande for dess framstellning
US5378612A (en) *	1990-05-11	1995-01-03	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Culture medium for production of recombinant protein
US5434185A (en) *	1993-05-17	1995-07-18	The University Of Kentucky Research Foundation	Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
US5405772A (en) *	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells
US5846529A (en) *	1993-08-23	1998-12-08	Nexell Therapeutics, Inc.	Infusion of neutrophil precursors for treatment of neutropenia
US6037174A (en) *	1993-08-23	2000-03-14	Nexell Therapeutics, Inc.	Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US5395822A (en) *	1993-09-20	1995-03-07	Izumi; Yukitoshi	Use of pyruvate to prevent neuronal degeneration associated with ischemia
US5593880A (en) *	1994-02-10	1997-01-14	Viratest International, Inc.	Dual-state nutritional medium for the transport and maintenance of cells
US5908782A (en) *	1995-06-05	1999-06-01	Osiris Therapeutics, Inc.	Chemically defined medium for human mesenchymal stem cells
EP0891419A4 (fr)	1996-03-12	2000-03-01	Life Technologies Inc	Additif pour milieu de culture nutritif pour cellules hematopoietiques
US6511848B2 (en) *	1996-04-17	2003-01-28	Winfried Albert	Process for producing and multiplying lymphocytes
US6833271B2 (en) *	1996-12-04	2004-12-21	Medi-Cult A/S	Serum-free cell culture media
AU2878200A (en) *	1999-02-11	2000-08-29	Schepens Eye Research Institute, Inc., The	Growth medium for human corneal endothelial cells
GB0003231D0 (en) *	2000-02-11	2000-04-05	Medi Cult As	Cell culture media
US20030096414A1 (en) *	2001-03-27	2003-05-22	Invitrogen Corporation	Culture medium for cell growth and transfection
KR20040032105A (ko) *	2001-06-04	2004-04-14	엠엘 래보러토리즈 피엘씨	재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법
US7087369B2 (en) *	2003-12-17	2006-08-08	The Regents Of The University Of California	Cornea preservation medium
US20080090753A1 (en)	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) *	2004-03-12	2008-04-10	Biodel, Inc.	Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) *	2004-03-12	2008-04-24	Biodel, Inc.	Rapid mucosal gel or film insulin compositions
ES2361559T3 (es)	2004-11-02	2011-06-20	Ares Trading S.A.	Medio de cultivo de células exento de suero para mamíferos.
US8273553B2 (en)	2004-11-02	2012-09-25	Ares Trading S.A.	Production of growth hormone in serum-free cell culture medium for mammalian cells
DK2368975T3 (en)	2004-12-23	2015-01-05	Medimmune Llc	Non-tumorigenic MDCK cell line for the propagation of viruses
US9074176B2 (en)	2006-01-13	2015-07-07	Two Cells Co., Ltd.	Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof
EP3255141B1 (fr) *	2006-07-13	2021-12-01	Wyeth LLC	Production de anticorps avec une gycosylation amelioree
EP2615167A1 (fr)	2006-09-15	2013-07-17	MedImmune, LLC	Méthode d'élimination de contaminants d'ADN des préparations de virus
US8361741B2 (en) *	2007-08-29	2013-01-29	Millipore Corporation	Serum-free growth medium for Acholeplasma laidlawii and methods for retention testing sterilizing grade filters
US8785173B2 (en)	2008-09-24	2014-07-22	Medimmune, Llc	Methods for purification of viruses
US9060927B2 (en)	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
EP2545928B1 (fr)	2010-03-10	2016-07-20	Two Cells Co., Ltd	Préparation de cellules contenant des cellules souches mésenchymateuses et procédé de production de celles-ci
JP6473079B2 (ja)	2012-05-02	2019-02-20	ライフテクノロジーズコーポレーション	高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
TW201630622A (zh)	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
US10119117B2 (en)	2016-01-28	2018-11-06	Nanogen Pharmaceutical Biotechnology Co., Ltd	Universal, glycosylation enhancer, completely chemically defined medium formulation
SG11201908891YA (en) *	2017-03-31	2019-10-30	Boehringer Ingelheim Int	Perfusion medium
WO2025033487A1 (fr) *	2023-08-09	2025-02-13	国立研究開発法人産業技術総合研究所	Procédé de contrôle de qualité de substitut de sérum ou de sérum

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4466917A (en) *	1981-02-12	1984-08-21	New York University	Malaria vaccine
US4544632A (en) *	1981-06-12	1985-10-01	Yuichi Yamamura	Human T cell lines and method of producing same
IL74298A (en) *	1982-05-13	1985-09-29	Israel State	Material obtainable from"green islands"for the prevention of virus replication in plants,its isolation and its use for plant immunization
US4604284A (en) *	1983-09-20	1986-08-05	Hoffmann-La Roche Inc.	Homogeneous immune interferon fragment
DE3584902D1 (de) *	1984-02-29	1992-01-30	Asahi Chemical Ind	Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
JPS6158584A (ja) *	1984-08-30	1986-03-25	Ube Ind Ltd	細胞増殖促進剤及び細胞増殖促進方法
JP2967117B2 (ja) *	1989-03-14	1999-10-25	旭化成工業株式会社	電子線硬化型導電性ペースト組成物

1987
- 1987-01-09 NO NO870095A patent/NO162160C/no not_active IP Right Cessation
- 1987-12-22 DK DK678687A patent/DK169765B1/da not_active IP Right Cessation
- 1987-12-24 KR KR1019870014892A patent/KR880009124A/ko not_active Ceased
- 1987-12-31 FI FI875793A patent/FI87230C/fi not_active IP Right Cessation
1988
- 1988-01-05 IL IL8502688A patent/IL85026A/xx not_active IP Right Cessation
- 1988-01-07 BR BR8800040A patent/BR8800040A/pt not_active IP Right Cessation
- 1988-01-07 AU AU10115/88A patent/AU596491B2/en not_active Ceased
- 1988-01-08 CA CA 556106 patent/CA1321961C/fr not_active Expired - Fee Related
- 1988-01-08 DE DE88300121T patent/DE3882540T2/de not_active Expired - Lifetime
- 1988-01-08 ES ES8800030A patent/ES2008411A6/es not_active Expired
- 1988-01-08 EP EP19880300121 patent/EP0274445B1/fr not_active Expired - Lifetime
- 1988-01-08 JP JP236888A patent/JPH0697996B2/ja not_active Expired - Fee Related
- 1988-01-08 AT AT88300121T patent/ATE92098T1/de not_active IP Right Cessation
- 1988-01-08 IT IT1902488A patent/IT1215675B/it active
- 1988-01-08 NZ NZ22313988A patent/NZ223139A/xx unknown
- 1988-01-11 US US07/142,069 patent/US5045467A/en not_active Expired - Lifetime
1990
- 1990-02-23 US US07/484,557 patent/US5045454A/en not_active Expired - Lifetime
1994
- 1994-02-28 JP JP5256094A patent/JP2524313B2/ja not_active Expired - Lifetime

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 69, no. 4, 1980, abstract no. 24569, Biological Abstracts, Inc., Philadelphia, PA, US; M. MOSKOWITZ et al.: "Growth and G1 arrest of sarcoma virus transformed cells in serum free media.", & J CELL PHYSIOL 100(3): 589-602. 1979 *
CHEMICAL ABSTRACTS, vol. 101, no. 7, 13th August 1984, page 394, abstract no. 52317g, Columbus, Ohio, US; A. HRADILEK et al.: "Iron uptake into HeLa cells adapted for growth in serum free medium", & STRUCT. FUNCT. IRON STORAGE TRANSP. PROTEINS, PROC. INT. CONF., 6th 1983, 121-2 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0314496A3 (fr) *	1987-10-29	1989-08-30	E.I. Du Pont De Nemours And Company	Production d'hybridomes
JPH01153085A (ja) *	1987-10-29	1989-06-15	E I Du Pont De Nemours & Co	ハイブリドーマ増殖用培地
EP0432952A1 (fr) *	1989-12-07	1991-06-19	Snow Brand Milk Products Co., Ltd.	Milieu de culture sans sérum
WO1993000423A1 (fr) *	1991-06-21	1993-01-07	Novo Nordisk A/S	Additif pour milieu de culture a base de chelate de fer
WO1994002592A1 (fr) *	1992-07-24	1994-02-03	Celltech Limited	Culture de cellules animales
US6593140B1 (en)	1992-07-24	2003-07-15	Lonza Group, Ag	Animal cell culture
WO1994025599A1 (fr) *	1993-04-26	1994-11-10	Biotechnolog Forschung Gmbh	Lignees cellulaires de mammiferes et procede de preparation de glycoproteines
EP0929662A4 (fr) *	1996-03-18	2002-12-04	Univ Pittsburgh	Milieux de culture cellulaire pour cellules de mamiferes
US8455246B2 (en)	1996-08-30	2013-06-04	Life Technologies Corporation	Serum-free mammalian cell culture medium, and uses thereof
US8198084B2 (en)	1996-08-30	2012-06-12	Life Technologies Corporation	Serum-free mammalian cell culture medium, and uses thereof
US9321996B2 (en)	1996-08-30	2016-04-26	Life Technologies Corporation	Serum-free mammalian cell culture medium, and uses thereof
US8815573B2 (en)	1996-08-30	2014-08-26	Life Technologies Corporation	Serum-free mammalian cell culture medium, and uses thereof
EP1482031A1 (fr) *	1996-08-30	2004-12-01	Invitrogen Corporation	Milieu de culture de cellules de mammifères exempt de sérum
EP2218775A1 (fr) *	1996-08-30	2010-08-18	Life Technologies Corporation	Méthode de production d'un polypeptide in vitro dans une cellule de mammifère dans un milieu de culture sans sérum and sans protéines
EP2243827A1 (fr) *	1996-08-30	2010-10-27	Life Technologies Corporation	Milieu de culture de cellules de mammifères exempt de sérum et ses utilisations
US8785194B2 (en)	1996-08-30	2014-07-22	Life Technologies Corporation	Serum-free mammalian cell culture medium, and uses thereof
WO1998024883A3 (fr) *	1996-12-04	1998-10-01	Medi Cult As	Milieux de cultures cellulaires sans serum
EP0872487A3 (fr) *	1997-04-18	1999-10-27	Bayer Corporation	Préparation de facteur VIII recombinant en milieu sans protéine
WO2001016294A3 (fr) *	1999-08-27	2001-09-07	Invitrogen Corp	Composes de liaison metallique et leur utilisation dans des compositions de milieu de culture cellulaire
US6767741B1 (en)	1999-08-27	2004-07-27	Invitrogen Corporation	Metal binding compounds and their use in cell culture medium compositions
EP2390263A1 (fr)	2005-08-26	2011-11-30	Ares Trading S.A.	Procédé pour la préparation d'interféron bêta glycosylé
US20110212523A1 (en) *	2008-11-11	2011-09-01	Yukio Kato	Differentiation-inducing culture medium additive and use thereof
EP3122770A4 (fr) *	2014-03-23	2017-08-23	Advantech Bioscience Farmacêutica Ltda.	Amélioration de l'expression de protéines recombinantes avec du cuivre
CN110835622A (zh) *	2018-08-16	2020-02-25	上海药明生物技术有限公司	用于调节哺乳动物细胞乳酸代谢的培养基及其应用
CN110835622B (zh) *	2018-08-16	2021-04-27	上海药明生物技术有限公司	用于调节哺乳动物细胞乳酸代谢的培养基及其应用

Also Published As

Publication number	Publication date
NZ223139A (en)	1991-09-25
DK169765B1 (da)	1995-02-20
DE3882540T2 (de)	1993-11-18
ATE92098T1 (de)	1993-08-15
DK678687D0 (da)	1987-12-22
IL85026A (en)	1992-09-06
ES2008411A6 (es)	1989-07-16
FI875793L (fi)	1988-07-10
FI875793A0 (fi)	1987-12-31
AU596491B2 (en)	1990-05-03
JPS63279786A (ja)	1988-11-16
DK678687A (da)	1988-07-10
DE3882540D1 (de)	1993-09-02
IT1215675B (it)	1990-02-22
FI87230C (fi)	1992-12-10
KR880009124A (ko)	1988-09-14
EP0274445B1 (fr)	1993-07-28
NO870095L (no)	1988-07-11
NO870095D0 (no)	1987-01-09
JPH0697996B2 (ja)	1994-12-07
FI87230B (fi)	1992-08-31
US5045467A (en)	1991-09-03
NO162160C (no)	1989-11-15
CA1321961C (fr)	1993-09-07
JP2524313B2 (ja)	1996-08-14
US5045454A (en)	1991-09-03
AU1011588A (en)	1988-07-14
NO162160B (no)	1989-08-07
IL85026A0 (en)	1988-06-30
EP0274445A3 (en)	1989-12-13
JPH06292570A (ja)	1994-10-21
IT8819024A0 (it)	1988-01-08
BR8800040A (pt)	1988-08-02

Legal Events

Date	Code	Title	Description
1988-05-28	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1988-07-13	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH DE FR GB LI NL SE
1989-10-24	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
1989-12-13	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE CH DE FR GB LI NL SE
1990-07-11	17P	Request for examination filed	Effective date: 19900515
1991-01-02	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MEDI-CULT A/S
1992-02-26	17Q	First examination report despatched	Effective date: 19920114
1993-04-21	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MEDI-CULT A/S
1993-06-10	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
1993-07-28	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB LI NL SE
1993-07-28	REF	Corresponds to:	Ref document number: 92098 Country of ref document: AT Date of ref document: 19930815 Kind code of ref document: T
1993-09-02	REF	Corresponds to:	Ref document number: 3882540 Country of ref document: DE Date of ref document: 19930902
1993-09-17	ET	Fr: translation filed
1994-06-02	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
1994-06-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
1994-07-20	26N	No opposition filed
1995-01-31	EAL	Se: european patent in force in sweden	Ref document number: 88300121.6
2002-01-01	REG	Reference to a national code	Ref country code: GB Ref legal event code: IF02
2003-11-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20031128 Year of fee payment: 17
2003-12-02	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20031202 Year of fee payment: 17
2004-01-05	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20040105 Year of fee payment: 17
2004-01-27	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: AT Payment date: 20040127 Year of fee payment: 17
2004-01-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20040130 Year of fee payment: 17
2005-01-08	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050108
2005-01-09	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050109
2005-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050131 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050131
2005-07-31	BERE	Be: lapsed	Owner name: MEDI-CULT A/S Effective date*: 20050131
2005-08-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050801
2005-08-30	EUG	Se: european patent has lapsed
2005-09-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2005-10-03	NLV4	Nl: lapsed or anulled due to non-payment of the annual fee	Effective date: 20050801
2006-11-06	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20061106 Year of fee payment: 20
2007-02-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20070228 Year of fee payment: 20
2007-12-31	BERE	Be: lapsed	Owner name: MEDI-CULT A/S Effective date*: 20050131
2008-01-30	REG	Reference to a national code	Ref country code: GB Ref legal event code: PE20
2008-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20070118 Year of fee payment: 20
2008-05-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20080107

Publication	Publication Date	Title
EP0274445B1 (fr)	1993-07-28	Additif de milieu de culture sans sérum et son utilisation
Moore et al.	1973	Cytogenetic analysis of human acute and chronic myeloid leukemic cells cloned in agar culture
JP3329387B2 (ja)	2002-09-30	培地濃縮物技術
US6261841B1 (en)	2001-07-17	Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells
Eliason et al.	1979	Erythropoietin-stimulated erythropoiesis in long-term bone marrow culture
US20080286862A1 (en)	2008-11-20	Physiochemical Culture Conditions for Embryonic Stem Cells
JP6990659B2 (ja)	2022-01-12	がん幹細胞（ｃｓｃ）含有細胞集団の培養のための化学的に規定された培地
JP2001505058A (ja)	2001-04-17	無血清細胞培養培地
KR20060076781A (ko)	2006-07-04	세포 배양 배지
EP1210410B1 (fr)	2008-01-16	Composes de liaison metallique et leur utilisation dans des compositions de milieu de culture cellulaire
Carswell et al.	2000	Low oxygen tension enhances the stimulation and proliferation of human T lymphocytes in the presence of IL-2
Darfler	1990	A protein-free medium for the growth of hybridomas and other cells of the immune system
EP0593539A1 (fr)	1994-04-27	Additif pour milieu de culture a base de chelate de fer
Yabe et al.	1987	Role of iron chelators in growth-promoting effect on mouse hybridoma cells in a chemically defined medium
JP2004135672A (ja)	2004-05-13	動物細胞又は組織を培養するための、ポリエチレングリコールを含んで成る組成物
Franke et al.	1984	In vitro cultivation of Dipetalonema viteae third-stage larvae: evaluation of culture media, serum, and other supplements
Chaplinski et al.	1986	Alteration in insulin receptor expression accompanying differentiation of HL-60 leukemia cells
Sato et al.	1989	Stimulation of monoclonal antibody production by human-human hybridoma cells with an elevated concentration of potassium or sodium phosphate in serum-free medium
Ralph	1981	Continuous cell lines with properties of mononuclear phagocytes
Grimstad et al.	1987	Cell‐surface laminin‐like molecules and α‐D‐galactopyranosyl end‐groups of cloned strongly and weakly metastatic murine fibrosarcoma cells
Donta	1975	Growth of functional glial cells in a serumless medium
Dell'Aquila et al.	1984	Response of malignant mammary cell lines to a growth inhibitor partially purified from plasma-derived human serum
Harris et al.	2020	Copper in tissue culture
Iizuka et al.	2000	Fe (III)-IDA induces proliferation and sustains functions of various types of cultured cells as a substitute for transferrin
Westfall et al.	1958	Effect on the medium of growth of clone NCTC 929 cells as suspensions in agitated flasks with simple fluid addition